The scaffold proteins connector enhancer of KSR (CNK) participate in Raf-, Rho-and NF-jB-dependent signalling and promote cell differentiation and invasion. In this study, we demonstrate that CNK1 downregulation inhibits, whereas CNK1 overexpression stimulates the proliferation of breast cancer cells and human embryonic kidney cells, respectively. This stimulatory effect depends on a functional phosphatidylinositol-3 kinase (PI3K) pathway because treatment of cells with the PI3K inhibitor, LY294002, abrogates CNK1-induced proliferation. CNK1 interacts with the PI3K effector Akt and knockdown of CNK1 decreases Akt activity in breast cancer cells. CNK1 controls Aktdependent phosphorylation and transcriptional activity of FoxO, which is a negative regulator of proliferation. Consistent with this, CNK1-induced cell proliferation is blocked by FoxO overexpression. Moreover, CNK1 regulates anchorage-independent proliferation and focus formation of breast cancer cells. CNK1 is predominantly localized at the plasma membrane of breast cancer cells, whereas in non-transformed mammary epithelial cells, CNK1 is cytoplasmatic. Accordingly, CNK1 is found preferentially at the plasma membrane in carcinoma in situ and invasive breast cancer tumours compared with normal breast tissue sections. Analysis of multiple breast cancer samples reveals that CNK1-negative tumours show less Akt activity. Thus, CNK1 promotes oncogenic signalling through Akt in breast cancer cell lines and tumours.
Connector enhancer of KSR (CNK) proteins are scaffold proteins conserved from flies to humans. The N-terminus (NT) of CNK is composed of a sterile alpha motive, a conserved region in CNK (CRIC) and a PSD95/DLG-1/ ZO-1 (PDZ) domain. The C-terminus (CT) harbours a proline-rich region and a pleckstrin homology domain ( Figure 1f ). CNK has first been described as a Rafinteracting protein that mediates Ras signalling in invertebrates (Therrien et al., 1998) . In Drosophila melanogaster, CNK has a pivotal role in proliferation or survival, differentiation and migration downstream of various receptor tyrosine kinases (Claperon and Therrien, 2007) . Through a complex mechanism involving speciesspecific elements, CNK allows Ras-and Src-dependent activation of Raf (Douziech et al., 2003; Laberge et al., 2005) . However, CNK is not essential for Ras signalling in Caenorhabditis elegans (Rocheleau et al., 2005) . Human CNK homologues regulate a variety of cellular signalling pathways. The ubiquitously expressed isoform CNK1 acts as a scaffold protein in Src-mediated Raf-1 activation and allows vascular endothelial growth factordependent stimulation of the Raf-MEK-ERK pathway (Ziogas et al., 2005) . Beside this, CNK1 interacts with the GTPase Rho and several components of the Rhosignalling pathway to facilitate JNK activation (Jaffe et al., 2004 (Jaffe et al., , 2005 Lopez-Ilasaca et al., 2005) . Moreover, CNK1 binds to the tumour suppressor RASSF1A and augments apoptosis on ectopic expression (Rabizadeh et al., 2004) . CNK1 also interacts with the angiotensin II type 2 receptor and may be involved in anti-proliferative and/or pro-apoptotic signalling, or may influence differentiation (Fritz and Radziwill, 2005) . Recently, CNK1 was described as a regulator of the nuclear factor (NF)-kB pathway thereby promoting cancer cell invasion (Fritz and Radziwill, 2010) . The neuronal isoform CNK2 has an essential function in nerve growth factor-induced, sustained stimulation of ERK leading to neuronal differentiation. But CNK2 is not required for epidermal growth factor-dependent, transient stimulation of ERK occurring during cell proliferation (Bumeister et al., 2004) . Taken together, these examples show that CNK proteins act in different signalling pathways and contribute to contextspecific cellular responses. Given that CNK proteins regulate signalling pathways controlling proliferation, differentiation, as well as apoptosis, and promote cell invasion, we asked whether CNK1 may be a universal, crucial regulator of oncogenic events in both breast cancer cell lines and tumours.
CNK1 regulates cell proliferation through a PI3K-dependent pathway
To address the function of CNK1 in cancer cells, we downregulated CNK1 by different short-hairpin RNAs in MDA-MB-231 breast cancer cells (Figure 1a ). CNK1 knockdown reduced proliferation by 29 and 55% in cells grown with or without serum, respectively (Figure 1b) . To evaluate the impact of CNK1 on anchorageindependent growth, control and CNK1-knockdown cells were cultured in three-dimensional Collagen I matrix (BD Biosciences, San Jose, CA, USA) in the presence of serum. Under these conditions, CNK1 downregulation decreased cell proliferation by 27% (Figure 1c ). In addition, CNK1 knockdown also impaired focus formation of MDA-MB-231 cells by 55% (Figure 1d ). Taken together, CNK1 regulates cell proliferation and cell transformation of breast cancer cells.
Cell proliferation is regulated by multiple pathways such as the Raf-MEK-ERK, NF-kB or phosphatidylinositol-3 kinase (PI3K)-Akt pathways (Baldwin, 2001; Karin et al., 2002; Vivanco and Sawyers, 2002; Dhillon et al., 2007) . CNK1 is involved in Raf-MEK-ERK and NF-kB signalling (Ziogas et al., 2005; Fritz and Radziwill, 2010) . Therefore, we used small-molecule inhibitors to identify the signalling pathways that 0 -gatccccGTAGTACTGCTAGTCATGGttcaagagaCCATGACTAGCAG TACTACtttttggaaa-3 0 ) to obtain stable polyclonal cell lines as described previously (Ziogas et al., 2005) . In addition, cells were transduced with lentiviral particles expressing a scrambled shRNA (shControl #2; sc-108080; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a pool of three CNK1 shRNAs (shCNK1 #2; 5 0 -CCATTGGGCCTAGAAATTCTTCAAGAGAGAATTTC TAGGCCCAATGGTTTTT-3 0 ; 5 0 -CTGACAGATCTGAGCATGTTTCAAGAGAACATGCTCAGATCTGTCAGTTTTT-3 0 and 5 0 -GGGAAGTAGTACTGCTAGTTTCAAGAGAACTAGCAGTACTACTTCCCTTTTT-3 0 ; sc-105220-V; Santa Cruz Biotechnology). The lentiviral-transduced cells were not selected with antibiotics. CNK1 downregulation is shown by western blot (WB) (anti-CNK1 antibody, (Ziogas et al., 2005) ). Molecular weight (kDa) is indicated by numbers to the left. (b) CNK1 knockdown decreases proliferation of MDA-MB-231 breast cancer cells. Cell proliferation was measured with an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay (#G3580, Promega, Madison, WI, USA). (c) CNK1 knockdown diminishes proliferation of cells grown in three-dimensional Collagen I. MDA-MB-231 cells were grown in Collagen I matrix and proliferation was measured as described (Kasper et al., 2007) , with the exception that Matrigel was replaced by Collagen I. (d) CNK1 downregulation inhibits focus formation. MDA-MB-231 cells were grown in complete medium and foci were counted. (e) CNK1 cooperates with PI3K in cell proliferation. MDA-MB-231 cells were treated with dimethylsulphoxide (DMSO), U0126 (12.5 mM, Promega), BAY11-7082 (2.5 mM, Calbiochem) or LY294002 (40 mM, Calbiochem, Merck Biosciences, Switzerland) for 72 h in serumfree medium and proliferation was assessed. (f) CNK1 overexpression stimulates cell proliferation. HEK293T cells (ATCC) were transfected with HA-Akt1 m/p (Andjelkovic et al., 1997) or HA-CNK1 constructs (Ziogas et al., 2005) , treated with DMSO or LY294002 (40 mM) for 24 h and proliferation was measured. Protein expression was monitored by western blot using anti-HA and anti-GAPDH antibodies (Santa Cruz Biotechnology). Schematic depiction of the CNK1 constructs is shown. Data in panels (b, e and f) or (c, d) show mean ± s.e.m. from three or two experiments carried out in triplicate, respectively; *Po0.05, **Po0.01, ***Pp0.0001. cooperate with CNK1 in promoting proliferation. Both the MEK inhibitor U0126 and the IkB kinase inhibitor BAY11-7082 decreased cell proliferation of serum-starved MDA-MB-231 control cells by 60% (Figure 1e ). CNK1 knockdown further and strongly decreased proliferation, indicating that CNK1 acts in a parallel pathway. This CNK1-dependent effect was observed throughout a concentration range of both inhibitors ( Supplementary Figures 1a and b) . Thus, CNK1-induced proliferation of breast cancer cells is independent of the NF-kB and the Raf-MEK-ERK pathways. In agreement with this, CNK1 is not required for epidermal growth factor-dependent ERK activation that results in cell proliferation (Bumeister et al., 2004) . Moreover, knockdown of CNK1 does not interfere with ERK phosphorylation in MDA-MB-231 cells, which overexpress a constitutively active Ras molecule (Fritz and Radziwill, 2010) . In contrast, CNK1 knockdown in the presence of the PI3K inhibitor LY294002 did not inhibit the proliferation rate as strong as in the presence of U0126 or BAY11-7082 (28% versus 64 and 59%, respectively; Figure 1e and Supplementary Figure 1c ). This shows that CNK1-knockdown cells are less sensitive to the PI3K inhibitor than control cells and suggests that CNK1 and PI3K act in the same pathway to drive cell proliferation.
To prove that CNK1 requires PI3K signalling to foster proliferation, we overexpressed CNK1 in human embryonic kidney (HEK) 293T cells in the presence or absence of LY294002 ( Figure 1f ). Overexpression of CNK1 wild type (WT) induced proliferation by 52%. This effect was as strong as the one caused by a myristoylated and palmitoylated constitutively active Akt1 molecule (Akt1 m/p) (Andjelkovic et al., 1997) , demonstrating that CNK1 is a powerful regulator of cell proliferation. Although expressed at similar levels, CNK1 NT stimulated proliferation even stronger than CNK1 WT, in contrast to CNK1 CT that was only a very weak activator of proliferation (121 and 10%, respectively). These results implicate an inhibitory function of CT that restricts the activating potential of the N-terminus in the full-length CNK1 molecule. The stimulation of cell proliferation by CNK1 WT, CNK1 CT and by Akt m/p was completely abrogated by LY294002. In contrast, the stimulatory effect of CNK1 NT was not fully reversed. Therefore, CNK1 may also participate in PI3K-independent pathways that foster proliferation through the N-terminus. However, the physiological full-length CNK1 protein depends only on PI3K to induce proliferation. Thus, CNK1 is a crucial, PI3K-dependent promoter of cell proliferation.
CNK1 regulates Akt activity and drives cell proliferation through the Akt-FoxO signalling axis
Akt is an important downstream effector of PI3K. Akt regulates proliferation as well as cell survival and PI3K-Akt signalling is frequently hyperactivated in human tumours including breast cancer (Vivanco and Sawyers, 2002) . To test whether CNK1 influences Akt activity, we analysed the phosphorylation status of Akt at S473 in MDA-MB-231 cells. This phosphorylation is crucial for Akt activity (Alessi et al., 1996) . We found reduced levels of phosphorylated Akt in CNK1-knockdown cells (Figure 2a ). Mammalian target of rapamycin (mTOR) complexed with Rictor was identified as the upstream kinase that phosphorylates Akt at S473 (Sarbassov et al., 2005) . mTOR complexed with Raptor acts downstream of Akt and is inhibited by the tuberous sclerosis complex 2 (TSC2) as well as the proline-rich Akt substrate of 40 kDa (PRAS40) Sancak et al., 2007) . Both TSC2 and PRAS40 are Akt substrates that become inactivated by Akt-dependent phosphorylation to enable mTOR activation Sancak et al., 2007) . In agreement with this, TSC2 and PRAS40 were less phosphorylated in CNK1-knockdown cells (Figure 2a ), meaning that mTOR is less active and correlating with reduced Akt phosphorylation at S473 in these cells.
Akt fosters proliferation through inhibitory phosphorylation of various anti-proliferative regulators such as the glycogen synthase kinase (GSK) 3 and FoxO transcription factors (Manning and Cantley, 2007) . CNK1 downregulation did not affect GSK3 phosphorylation in MDA-MB-231 cells (Figure 2a) , suggesting that GSK3/b-catenin signalling is not influenced by CNK1. However, phosphorylation of FoxO proteins was diminished in CNK1-knockdown cells. In line with this, the Akt-regulatory proteins SIN1 and ProF have been found to promote FoxO but not GSK3 phosphorylation by Akt (Jacinto et al., 2006; Fritzius and Moelling, 2008) . It is interesting that CNK1 downregulation decreased FoxO1 and FoxO3a phosphorylation at T24 and S32, but not at S256 and S253, respectively. This FoxO phosphorylation pattern has also been observed in murine embryonic fibroblasts and it has been proposed that S473 phosphorylation determines substrate utilization (Jacinto et al., 2006) . Phosphorylation of T24/S256 in FoxO1 and S32/S253 in FoxO3a by Akt creates binding sites for 14-3-3 proteins. FoxO complexed with 14-3-3 is sequestered in the cytoplasm, thereby preventing FoxO-dependent transcriptional activation and thus promoting cell proliferation (Calnan and Brunet, 2008) . Impaired Akt activity gauged by phosphorylation at S473 correlated with diminished FoxO phosphorylation at T24/S32 and increased FoxO1 accumulation in the nucleus of CNK1-knockdown cells, supporting the physiological relevance of CNK1 in Akt-dependent regulation of FoxO activity in MDA-MB-231 cells (Figure 2b) . Consistent with this, we found that forced expression of CNK1 almost completely inhibited FoxO transcriptional activity in luciferase reporter assays, in which FoxO activity has been induced by LY294002 (Figure 2c ). FoxO transcription factors inhibit proliferation through induction of cell-cycle arrest (Huang and Tindall, 2007 ). Therefore, we tested whether CNK1-dependent cell proliferation was blocked by forced expression of FoxO. In HEK293T cells, expression of CNK1 WT, CNK1 NT and CNK1 CT activated proliferation by 49, 147 and 16%, respectively (Figure 2d ). Similar to LY294002, the stimulatory effect of CNK1 WT and CNK1 CT was completely abrogated by coexpression of FoxO1, whereas CNK1 NT was only partially inhibited by FoxO1 overexpression. Therefore, CNK1 acts upstream of FoxO and stimulates proliferation through Akt-dependent phosphorylation and inactivation of FoxO transcription factors.
CNK1 interacts with Akt
As CNK1 controls Akt activity and substrate determination, we hypothesized that CNK1 interacts with Akt. In HEK293T cells, overexpressed CNK1 WT, NT and CT coimmunoprecipitated endogenous Akt (Figure 3a) . The coimmunoprecipitated Akt was phosphorylated at S473, suggesting that CNK1 can bind to the active form of Akt. Akt predominantly interacted with the Nterminus of CNK1 and to a much lesser extend with CNK CT (normalized amounts of Akt coimmunoprecipitated with CNK1 WT, NT and CT were 1.0, 1.2 and 0.2, respectively). These experiments do not exclude that CNK1 and Akt may be bridged by an additional factor coimmunopurified. It is interesting that CNK1 WT and CNK1 NT, but not CNK1 CT, strongly induced the proliferation of HEK293T cells (Figures 1f  and 2d) , suggesting that the ability to bind Akt correlates with the potential of CNK1 to stimulate cell proliferation.
We confirmed the interaction between Akt and overexpressed CNK1 with endogenous proteins expressed in MDA-MB-453 breast cancer cells (Figure 3b) . The specificity of the interaction is proven by a competition experiment using a blocking peptide that strongly reduced the amount of coimmunoprecipitated CNK1. In addition to MDA-MB-453 cells, CNK1 coimmunoprecipitated with Akt in MDA-MB-231 breast cancer and HeLa cervical cancer cells (Supplementary Figure 2 ). Furthermore, immunoprecipitated Akt but not the p85 subunit of PI3K copurified CNK1, even though p85 was able to bind to the p110 subunit of PI3K (Figure 3c ). The amount of CNK1 bound by p85 is comparable to that bound by an anti-HA antibody and therefore can be considered as unspecific binding. Consistently, CNK2 interacts neither with the p85 nor the p110 subunit of PI3K (Lanigan et al., 2003) . This indicates that Akt is the target of CNK1 in the PI3K-Akt signalling pathway.
CNK1 interacted with activated Akt (Figure 3a ). Therefore, we tested whether the interaction was sensitive to the PI3K inhibitor LY294002 or the Akt inhibitor Akt-I-1/2. Reduced phosphorylation of Akt at Ser 473 correlated with reduced binding to CNK1 in MDA-MB-453 cells, confirming that CNK1 predominantly interacts with activated Akt (Figure 3d ). Akt-I-1/ 2 displayed a stronger inhibitory effect than LY294002. This may be explained by the fact that Akt-I-1/2 targets the pleckstrin homology domain of Akt, which may bind to CNK1 (Barnett et al., 2005) . Thus, the phosphorylation state of Akt regulates the interaction with CNK1.
CNK1 expression correlates with Akt activity in breast cancer
CNK1 interacts with Akt and determines Akt activity in breast cancer cells. This led us to examine CNK1 expression and Akt phosphorylation in MCF10A normal epithelial cells and MCF-7, MDA-MB-231 and MDA-MB-453 breast cancer cells. CNK1 expression was equal in MCF10A, MCF-7 and MDA-MB-231 cells but strongly elevated in the MDA-MB-453 cells (Figure 4a ). Phospho-S473 Akt was only detectable in breast cancer cells, with the highest phosphorylation level in MDA-MB-453 cells that also displayed the highest CNK1 expression. Generally, breast cancer cells showed an increased Akt expression. (c) CNK1 localizes to the plasma membrane in DCIS and invasive breast carcinoma samples. Twenty-four formalin-fixed, paraffin-embedded tissue samples from normal breast tissue, in situ, and invasive breast cancers were retrieved from the archives of the Institute of Surgical Pathology, University Hospital Zurich. For immunohistochemistry (top panels), the monoclonal anti-CNK1 antibody (Transduction Laboratories, San Diego, CA, USA; 1:50 dilution) was adjusted to the BondMax system (Leica Microsystems, Medite, Burgdorf, Germany) on a small series of invasive breast cancer samples as previously described (Theurillat et al., 2007) . The corresponding histology is shown in haematoxylin and eosin staining (bottom panels). The numbers of sections showing cytoplasmic (cyt) and membranous (mem) CNK1 staining are depicted below. (d) CNK1-negative tumours display less Akt phosphorylation at S473. The TMA containing 344 breast cancer samples was described earlier (Theurillat et al., 2007 As phosphorylation and activation of Akt occurs at the plasma membrane (Bellacosa et al., 1998) , we analysed the subcellular localization of CNK1 in both normal and breast cancer cells. In all breast cancer cell lines tested, CNK1 was principally localized in the membrane fraction. Conversely, CNK1 was mainly found in the cytosolic fraction with only a minor amount in the membrane fraction in MCF10A cells (Figure 4b) . As shown before, CNK1 promotes Akt activation (Figure 2a) . Therefore, membrane-targeted CNK1 may account for the fact that Akt is phosphorylated in breast cancer cells but not in mammary epithelial cells.
To translate these findings into clinical relevant settings, we examined CNK1 localization in breast cancer samples by immunohistochemistry. In normal breast tissue, 100% of sections (n ¼ 24) showed cytoplasmatic and only 17% sections (n ¼ 4) showed additional membranous CNK1 staining (Figure 4c , left panels). In contrast, membranous CNK1 staining occurred in 58% of ductal carcinoma in situ (DCIS) or invasive carcinoma samples (Figure 4c , middle and right panels, respectively). Cytoplasmic CNK1 staining was observed in 83% DCIS and 70% invasive carcinoma sections, indicating that the fraction of cytosolic CNK1 decreases in late-stage tumours. Thus, in cancer cells, CNK1 translocates to the plasma membrane, which is the compartment of Akt activation.
Finally, we investigated the relationship between CNK1 expression and Akt S473 phosphorylation in breast cancer samples. On a tissue microarray composed of 327 examinable breast cancer samples, we found 20 samples (6%) without detectable CNK1 expression (Figure 4d ). Within the 307 CNK1-positive tumours, 21% of the cases showed a diffuse, 37% a moderate and 42% no phospho-S473 Akt staining (see Figure legend for scoring parameters). Among the 20 CNK1-negative tumours, 15% of the samples displayed a diffuse, 25% a moderate and 60% no phospho-S473 Akt staining. This means that the fractions of samples with diffuse and moderate phospho-S473 Akt staining decrease by 29 and 32%, respectively, whereas phospho-negative samples rise by 43% in CNK1-negative tumours. Moreover, the small number of CNK1-negative tumours reflects the importance of CNK1 for Akt activity and tumour development.
In summary, we identified CNK1 as an essential regulator of Akt-dependent cell proliferation. In tumour cell lines and in breast cancer tissue, CNK1 localizes to the plasma membrane and interacts with Akt, supporting the functional relationship of both proteins. Owing to the fact that PI3K-Akt signalling is hyperactivated in various human cancers and that CNK1 also regulates cellular transformation, our results indicate that CNK1 may serve as a target for cancer therapy of certain tumour types including breast cancer.
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